Latest / Pharmacy Podcast Network / A Pharmacist's Breast Cancer Story: How Pharmacogenomics Testing Shaped Her Treatment and Factors Influencing PGx Testing Becoming a Standar
Transcript
- 0:05Speaker 1: You are listening to the global network of podcasters dedicated
- 0:08Speaker 1: to the pharmacy profession. Welcome to the Pharmacy podcast Network.
- 0:27Speaker 2: In a world where one size fits all medications dominate
- 0:31Speaker 2: the pharmaceutical industry, precision medicine brings a ray of hope
- 0:34Speaker 2: for those seeking customized healthcare. Pharmacists have a unique opportunity
- 0:38Speaker 2: to help people in need of specialized testing to ensure
- 0:41Speaker 2: medications work is intended. Welcome to Precision Help in PGX,
- 0:46Speaker 2: where we unravel the wonders of precision medicine and its
- 0:49Speaker 2: potential to revolutionize the way we approach pharmacy care. Get
- 0:53Speaker 2: ready to uncover the secrets behind pharmacogenomics and how it's
- 0:57Speaker 2: transforming lives one genome amount of time.
- 1:08Speaker 3: I am your host, doctor Becky Winslow, and you're listening
- 1:11Speaker 3: to the Precision Health and PGS podcast. In case you're
- 1:15Speaker 3: wondering what happened to the PGX for pharmacist podcasts, You're
- 1:19Speaker 3: listening to it right now, only with a different name,
- 1:23Speaker 3: with the goal to broaden our listenership and content to
- 1:26Speaker 3: include non pharmacogenomics based precision health topics. My co host,
- 1:31Speaker 3: doctor Bana Sarami and I decided to rebrand the podcast
- 1:36Speaker 3: no different than we did on the PGX for Pharmacist Podcasts.
- 1:40Speaker 3: We will continue to explore all things pharmacogynomics related, including
- 1:45Speaker 3: pharmacist role in PGX, and our mission still includes educating
- 1:50Speaker 3: and advocating for PGX. We will continue to accomplish this
- 1:54Speaker 3: mission through exclusive interviews with highly qualified and well experience
- 2:00Speaker 3: as industry leaders. Today's special guests is doctor Angelo Casano,
- 2:08Speaker 3: farm Fusion founder and owner. We will discuss doctor Cassano's
- 2:13Speaker 3: personal pharmacogenomics testing and how the results impacted her breast
- 2:17Speaker 3: cancer treatment. Doctor Cassano or Angela as I know you,
- 2:22Speaker 3: thanks so much for joining us today on the podcast.
- 2:25Speaker 3: You and I go way way back, a long way other.
- 2:29Speaker 3: Twenty years have passed since we were in school and
- 2:32Speaker 3: our capside fraternity together at Campbell University School of Pharmacy.
- 2:37Speaker 3: I feel like it was just last week. Time has
- 2:39Speaker 3: really flown and neither of us imagined that I would
- 2:43Speaker 3: have a podcast and I would be interviewing you as
- 2:46Speaker 3: a guest. So please introduce yourself and share briefly your education,
- 2:52Speaker 3: work and accomplishments with our audience. And for now, let's
- 2:56Speaker 3: say the Cap Size Stories for another episode. My audience
- 3:00Speaker 3: continues to respect me.
- 3:04Speaker 4: Yes, absolutely, thank you so much for inviting me to
- 3:07Speaker 4: be on the podcast today, Becky.
- 3:09Speaker 5: My name is Angela Cassano, and as Becky mentioned, we
- 3:13Speaker 5: met many years ago at Campbell University and we're brothers
- 3:17Speaker 5: in Capasi at that fine university. After I left Campbell,
- 3:23Speaker 5: I went on to MCV or VCU as most people.
- 3:27Speaker 4: Know it now, and did two residencies.
- 3:31Speaker 5: I did a general residency and then did a Medpeede's residency,
- 3:37Speaker 5: so half of my second year was in adult medicine
- 3:40Speaker 5: and half was in pediatrics. It was made up residency
- 3:45Speaker 5: that was modeled after the Medpeed's medical residency that was
- 3:50Speaker 5: very popular at that institution. Once I left there, I
- 3:55Speaker 5: went into hospital pharmacy.
- 3:57Speaker 4: That was my love, the area that I love working
- 4:01Speaker 4: in and with, and.
- 4:04Speaker 5: Predominantly worked in community hospitals from that point forward and
- 4:11Speaker 5: with a subspecialty in pediatrics indianatal pharmacy, and then reached
- 4:19Speaker 5: the clinical manager stage much faster than I probably had
- 4:24Speaker 5: any business reaching and went into to that area of
- 4:28Speaker 5: management and determined that that I wasn't a great fit there.
- 4:34Speaker 5: And while I was on maternity leave with my daughter,
- 4:39Speaker 5: I decided to step down from a leadership role, but
- 4:42Speaker 5: was instead offered a medication safety officer role, which was
- 4:46Speaker 5: a brand new a foray for pharmacy, if you will,
- 4:51Speaker 5: back in the early two thousands, and it was really
- 4:55Speaker 5: a pioneer type role that I found to be very rewarding.
- 4:59Speaker 4: It awed me to still.
- 5:00Speaker 5: Focus a lot on pediatrics indianatology since that is a
- 5:04Speaker 5: high risk population when it comes to medication safety, and
- 5:09Speaker 5: my two areas that I focused on predominantly there were
- 5:15Speaker 5: smart and fusion pumps. We were a beta site for
- 5:18Speaker 5: smart infusion pumps and that was the original advent of
- 5:23Speaker 5: USP seven nine seven, so getting five different hospitals within
- 5:27Speaker 5: our system up to speed on sterile compounding compliance. I
- 5:34Speaker 5: never intended to be a business owner or an entrepreneur.
- 5:39Speaker 5: I skipped that class honestly in pharmacy school because.
- 5:45Speaker 4: It was really focused on owning your own pharmacy and
- 5:52Speaker 4: I knew that that I wanted to be in the hospital.
- 5:54Speaker 5: Realm, so I didn't pay a lot of attention to
- 5:58Speaker 5: entrepreneurship or business.
- 5:59Speaker 4: As as you will.
- 6:02Speaker 5: But then found myself in a situation where we were
- 6:05Speaker 5: moving across country and it just made sense and I
- 6:09Speaker 5: relied on my network and found a lot of people
- 6:13Speaker 5: needing the skills that I had, and I started form Fusion.
- 6:18Speaker 4: Consulting in two thousand and five and really.
- 6:22Speaker 5: Intended to do that until our daughter went to kindergarten
- 6:25Speaker 5: and she is now a junior in college. So I
- 6:28Speaker 5: have loved everything about being an entrepreneur and building that
- 6:35Speaker 5: business and learning that skill set. But along came cancer
- 6:39Speaker 5: very early in that time, and that really changed my
- 6:43Speaker 5: outlook on everything but life in particular, and I think
- 6:47Speaker 5: that's probably why Becky has me here today more so
- 6:51Speaker 5: than being an entrepreneur.
- 6:54Speaker 3: Absolutely, So thank you for introducing yourself, and you know
- 6:59Speaker 3: your joy is an entrepreneur, because honestly, we want to
- 7:04Speaker 3: share that as well on our podcast. You know, I
- 7:08Speaker 3: too never expected I would be an entrepreneur, but anyone
- 7:11Speaker 3: that knows me well would say traits in my personality
- 7:15Speaker 3: suggested that I was destined to blaze trails outside of
- 7:19Speaker 3: traditional pharmacy, just like you have. So we'll have another
- 7:23Speaker 3: podcast episode on entrepreneurism, but let's jump right into our
- 7:28Speaker 3: discussion today because your message is so inspiring and it's
- 7:36Speaker 3: so applicable to what we talk about on our podcast
- 7:39Speaker 3: and I want to make sure our audience gets as
- 7:42Speaker 3: much as possible out as this episode as we can. So, Angela,
- 7:48Speaker 3: you mentioned that you had a turn of events in
- 7:51Speaker 3: your life that certainly reshaped your work life, your personal life.
- 7:57Speaker 3: Can you start by recounting for your breast cancer diagnosis,
- 8:02Speaker 3: including the year you were diagnosed. I mean, I'm know
- 8:05Speaker 3: receiving such a diagnosis had to be difficult.
- 8:10Speaker 5: Absolutely it was difficult, but it was something that changed
- 8:15Speaker 5: my life, my family's life forever, and just the type
- 8:19Speaker 5: of thing that I want to.
- 8:21Speaker 4: Share because there certainly were everyone's.
- 8:23Speaker 5: Cancer journey is very different, but there were certainly some
- 8:27Speaker 5: lessons learned along the way from mine.
- 8:31Speaker 4: I was thirty years old and it was two thousand
- 8:35Speaker 4: and seven, and I just was one year into my business.
- 8:40Speaker 5: I had a one year old at home, and I
- 8:44Speaker 5: started feeling pain in my wrist, my lower arm, and
- 8:50Speaker 5: I really thought it was carpal tunnel syndrome. I had
- 8:53Speaker 5: been spending really nights putting together a course on pharmacology
- 8:58Speaker 5: for a physician assistant college and was working a lot,
- 9:03Speaker 5: typing a lot, and so my husband and I reset
- 9:07Speaker 5: my entire office, We changed everything, got myself comfortable and
- 9:12Speaker 5: ergonomically set up, and the pain didn't stop.
- 9:17Speaker 4: And it was at that point that I really.
- 9:19Speaker 5: Started and if you were able to see me and
- 9:22Speaker 5: not just hear me, I started feeling the pain was
- 9:25Speaker 5: really more in my elbow area, and I would trace
- 9:29Speaker 5: up from that back up to my axilla area and
- 9:33Speaker 5: then across and so I could tell that the pain
- 9:35Speaker 5: was actually coming from higher and it was a very
- 9:39Speaker 5: sensitive nerve pain.
- 9:41Speaker 4: And then one of the times when I did that,
- 9:43Speaker 4: I swiped across my breast and felt the tiniest lump
- 9:47Speaker 4: and thought, that can't possibly really be a lump. It
- 9:51Speaker 4: was no larger than the size of a pixel eraser.
- 9:54Speaker 5: I was thirty one years old, I had no family history,
- 9:58Speaker 5: and but then I felt again and again. And my
- 10:03Speaker 5: husband happens to be a surgeon. He had done plenty
- 10:07Speaker 5: of breast exams in general surgery, so, you know, standing
- 10:11Speaker 5: in the kitchen, I was like, can you can.
- 10:15Speaker 4: You check this?
- 10:16Speaker 5: So he's you know, he's checking for things, and you know,
- 10:21Speaker 5: the most awkward situation, and found the lump in that
- 10:25Speaker 5: zella as well. I happened to have a friend who
- 10:29Speaker 5: was an obi. I went to her, or I called her.
- 10:33Speaker 5: She set me up with her partner and I went in,
- 10:36Speaker 5: got checked and did the exam, and he couldn't feel
- 10:41Speaker 5: anything and said, no, Renee's already set up this ultrasound
- 10:46Speaker 5: in mammogram. Why don't you go on and do that.
- 10:48Speaker 5: But I don't feel anything. You're too young, can't possibly
- 10:51Speaker 5: be cancer.
- 10:53Speaker 4: And so I went.
- 10:56Speaker 5: Was sitting up at the was sitting upright at the
- 11:00Speaker 5: ultrasound and the ultrasound texts listened to my history, my
- 11:04Speaker 5: husband's background.
- 11:05Speaker 4: Said you sound like you know what you're talking about.
- 11:07Speaker 4: Where is this? I pointed to it, and she put
- 11:12Speaker 4: the ultrasound probe right on it.
- 11:15Speaker 5: The mamogram had been normal, which is not surprising with
- 11:18Speaker 5: Den's breast tissue.
- 11:19Speaker 4: Thirty year old. She put the.
- 11:21Speaker 5: Ultrasound probe on it. She's like, yep, you're right, it's
- 11:25Speaker 5: right there. They fell under that silla where I pointed.
- 11:29Speaker 5: She's like, yep, you're right, it's right there, and can
- 11:31Speaker 5: show me on the screen.
- 11:34Speaker 4: And when I went out, went to.
- 11:36Speaker 5: The restroom, came out of the restroom and everybody at
- 11:40Speaker 5: the radiology practice was standing for whatever reason where they
- 11:45Speaker 5: reviewed films was right outside the restroom, and they were
- 11:49Speaker 5: all talking about it and didn't realize.
- 11:50Speaker 4: I was standing behind them.
- 11:52Speaker 3: Oh wow, at which point I.
- 11:54Speaker 5: Burst into tears, dialed my husband and handed the doctor
- 11:58Speaker 5: my phone. He has to knock come with me because
- 12:02Speaker 5: we had been told two hours earlier it was nothing.
- 12:05Speaker 4: Uh, and so all I heard was.
- 12:08Speaker 5: The Peanuts teacher character go wanh lah lah lah lah,
- 12:11Speaker 5: and I let my husband deal with the news. My
- 12:17Speaker 5: one takeaway from that, and I know it's not genomics related,
- 12:21Speaker 5: is ladies or others who love ladies. If you feel
- 12:27Speaker 5: something in your body, whether it's in your breast or
- 12:30Speaker 5: somewhere else, make sure that the person examining you is
- 12:35Speaker 5: examining you in the same position that you feel said lump.
- 12:42Speaker 5: In the doctor's defense, when you go for an ob
- 12:46Speaker 5: appointment or a guide appointment, they have you lay down
- 12:50Speaker 5: and lift your arm above your head. In that position,
- 12:53Speaker 5: you couldn't feel the lump. So he didn't feel anything.
- 12:57Speaker 5: But as soon as I but every time I felt
- 13:00Speaker 5: it at home or my husband could feel it, or
- 13:02Speaker 5: the ultrasoundtech, I was standing or sitting upright and it
- 13:06Speaker 5: was you could almost see it.
- 13:08Speaker 4: Oh wow, of the skin. So that is my number
- 13:12Speaker 4: one life saving takeaway is if.
- 13:15Speaker 5: You feel something and you're having somebody else tactilely feel
- 13:19Speaker 5: it as well be in the exact same position. So
- 13:25Speaker 5: from there I launched into a diagnosis of stage two
- 13:32Speaker 5: B breast cancer and I'll let Becky pick up from there.
- 13:37Speaker 3: Sure. Yeah, thanks for sharing that great tip with our audience.
- 13:41Speaker 3: I had never thought about position, you know, when you're
- 13:45Speaker 3: being examined in the doctor's office, versus how you might
- 13:50Speaker 3: detect it at home. So that's great information. And I
- 13:54Speaker 3: love your self advocacy story. Hearing you talk about advocating
- 13:59Speaker 3: for your self really puts a big grin on my
- 14:02Speaker 3: face because I teach patients how to advocate for themselves
- 14:06Speaker 3: and their health care. So just to get jump started
- 14:09Speaker 3: into the treatment, what breast cancer treatment did your physician
- 14:14Speaker 3: prescribe prior to your firm ecosyonomics test.
- 14:19Speaker 5: Sure, I had the blessing and curse you might say
- 14:26Speaker 5: of being connected in the medical world. I did have
- 14:30Speaker 5: some connectivity that unfortunately a lot of patients don't have.
- 14:36Speaker 5: But in those cases, being connected immediately before people can
- 14:40Speaker 5: have a lot of time to really think academically about
- 14:43Speaker 5: how to manage someone's care doesn't always help either. And
- 14:51Speaker 5: my doctor went straight for a lumpectomy. She said, I
- 14:55Speaker 5: can do all the testing we can. You know, I
- 14:58Speaker 5: could do it biopsy, but I can tell you based
- 15:00Speaker 5: on the ultrasound scans and what we're feeling, that I wouldn't.
- 15:06Speaker 4: Be confident if it came back as the non.
- 15:10Speaker 5: And so she went ahead and did a lumpect to
- 15:12Speaker 5: me at that point.
- 15:16Speaker 4: And did full lift of removal in that.
- 15:20Speaker 5: Right side, which was probably aggressive by some people's standards,
- 15:24Speaker 5: but again, I was married to a surgeon and still and.
- 15:29Speaker 4: So we like to cut things out. So that's a
- 15:31Speaker 4: little different than people might have gone for.
- 15:34Speaker 5: First it's kind of a shift in thinking at that point,
- 15:39Speaker 5: and that was really when people were starting to do
- 15:42Speaker 5: chemotherapy first, to watch.
- 15:45Speaker 4: Tumor shrink and make sure that you were getting a response.
- 15:49Speaker 4: And my second opinion.
- 15:51Speaker 5: When we went out to a larger medical center, she
- 15:55Speaker 5: was very upset that the tumor had already been removed,
- 15:59Speaker 5: but nonetheless I did the lympectomy.
- 16:05Speaker 4: She knew she didn't have clear borders.
- 16:07Speaker 5: At that point, and so we knew a mastectomy was
- 16:11Speaker 5: in my future, but she wanted to go ahead and
- 16:13Speaker 5: start chemotherapy right away. I did adrians and cyclothosphomide for
- 16:19Speaker 5: four rounds and did tax all in a very.
- 16:23Speaker 4: Non traditional fashion for that time.
- 16:27Speaker 5: It would have typically been weekly for twelve weeks, and
- 16:32Speaker 5: I did it every other week for eight. And the
- 16:35Speaker 5: reason for that, and unbeknownst to my doctor, was my
- 16:39Speaker 5: husband was accepting a position out of state and this
- 16:44Speaker 5: was before the Affordable Care.
- 16:46Speaker 4: Act and he did not have.
- 16:52Speaker 5: We needed to have my chemotherapy and all treatment associated
- 16:56Speaker 5: with it done prior to moving, stentially losing insurance right right, So.
- 17:04Speaker 4: We were aggressive.
- 17:05Speaker 5: My physician asked me if if I would tell him
- 17:08Speaker 5: why I wanted to go that route, and he was
- 17:11Speaker 5: a major referral source for my husband, so I kindly said, no,
- 17:15Speaker 5: I can't tell you, but I will be honest and
- 17:18Speaker 5: if I start having neuropathy, we will back.
- 17:20Speaker 4: Around and go the week. So that was the course
- 17:27Speaker 4: that we set.
- 17:28Speaker 5: Off on, and then that was to be followed I
- 17:30Speaker 5: was premenopausal. That was going to be followed by tamoxifen
- 17:34Speaker 5: for five years.
- 17:37Speaker 3: So it certainly sounds like being a clinician and being
- 17:43Speaker 3: married to a clinician surrounded by clinicians really impacted your
- 17:48Speaker 3: treatment journey. And I mean, like you said, not all
- 17:51Speaker 3: patients have that. And you know, I'm sure you guys
- 17:55Speaker 3: researched everything you could get your hands on to make.
- 18:01Speaker 4: We honestly didn't. Oh didn't you Okay. The two things
- 18:06Speaker 4: we researched were my option. The chemotherapy was pretty standard.
- 18:14Speaker 5: I had a very dear friend and still rely on
- 18:17Speaker 5: her that was an oncology specialist, and I relied on
- 18:20Speaker 5: her background and her expertise. It would have taken me
- 18:25Speaker 5: had not looked at oncology treatments in years.
- 18:28Speaker 4: It would have taken entirely.
- 18:29Speaker 5: Too long to be educated on that, and so I
- 18:33Speaker 5: relied very heavily on my network for that information. The
- 18:39Speaker 5: and that was pretty standard. It's not the standard, is
- 18:42Speaker 5: my understanding for to be breast cancer now, but it
- 18:45Speaker 5: was time, and so we went with that and hit hard.
- 18:49Speaker 5: The two things that I researched independently and that my
- 18:53Speaker 5: husband did as well, were my option were a massed
- 19:01Speaker 5: ectomy and no radiation, or a lumpectomy and radiation to
- 19:07Speaker 5: the area. And when we researched that, what we found,
- 19:13Speaker 5: and it's still fairly true, is that the majority of
- 19:17Speaker 5: the research on secondary malignancies from radiation is not in
- 19:26Speaker 5: thirty year olds. It is most much of the breast
- 19:30Speaker 5: cancer research, particularly at that time was in sixty five
- 19:34Speaker 5: and older, and so cancer twenty years later, which had
- 19:38Speaker 5: been my goal to live at least another twenty years,
- 19:41Speaker 5: and we're getting mighty close to that is.
- 19:46Speaker 4: And those many of those.
- 19:47Speaker 5: People you know had lived a had died in natural
- 19:52Speaker 5: death at the twenty mark mark, not.
- 19:54Speaker 4: Some a recurrence of a cancer.
- 19:56Speaker 5: Sure, and my husband started seeing patients that were young
- 20:01Speaker 5: cancer patients that were coming to him as a thoracic
- 20:05Speaker 5: surgeon with secondary thoracic malignancies in the exact same place
- 20:11Speaker 5: the radiation had occurred as a child or as a
- 20:16Speaker 5: younger individual, And so based on that, we chose to
- 20:21Speaker 5: do a mastectomy and not do radiation because we had
- 20:28Speaker 5: that choice. Again, that was very anecdotal, but that was
- 20:34Speaker 5: one thing that we researched very heavily, and unfortunately there
- 20:37Speaker 5: was not There wasn't research.
- 20:39Speaker 4: That reflected me.
- 20:41Speaker 3: Right.
- 20:42Speaker 5: The other thing that I researched quite a bit was
- 20:45Speaker 5: the genomics portion of it, and we can get into that, yeah, sure.
- 20:51Speaker 3: So just for our audience's benefit. Tamoxifen is an FDA
- 20:58Speaker 3: approved estrogen. Agonis antagonists. That's the medication that Angela mentioned
- 21:04Speaker 3: that she took for her cancer. It's indicated for the
- 21:10Speaker 3: treatment of adult patients with estrogen receptor positive metastatic breast cancer.
- 21:16Speaker 3: It's also indicated for adjuvant treatment of adult patients with
- 21:21Speaker 3: early stage estrogen receptor positive breast cancer. It's indicated to
- 21:26Speaker 3: reduce the risk of invasive breast cancer following breast surgery
- 21:31Speaker 3: and radiation, and an adult women with adultal carcinoma in situ.
- 21:36Speaker 3: And lastly, it's indicated to reduce the incidence of breast
- 21:41Speaker 3: cancer and adult women at high risk. So, now that
- 21:47Speaker 3: I've defined tomoxifen for our audience and what it's indicated for,
- 21:53Speaker 3: let's focus a bit on the pharmacogenomics. As Angela mentioned
- 21:57Speaker 3: that she did research on so. The CYP two D
- 22:02Speaker 3: six enzyme metabolizes a quarter of all prescribed drugs, is
- 22:07Speaker 3: one of the main enzymes involved in converting to moxifin
- 22:11Speaker 3: into its major active metabolite, indoxofin, and genetic variation in
- 22:18Speaker 3: the CYP two D six gene may lead to increased
- 22:22Speaker 3: or ultra rapid metabolizer status, they can lead to decreased
- 22:28Speaker 3: or intermediate metabolizer status or absent or poor metabolizer enzyme activity,
- 22:37Speaker 3: and individuals who are intermediate or poor metabolizers may have
- 22:41Speaker 3: reduced plasma concentrations of indoxofin, and that may those patients
- 22:48Speaker 3: may benefit less from demoxifen therapy. And just to reference
- 22:55Speaker 3: our resources for pharmacogenomics, a quick look at the FDA
- 23:01Speaker 3: approved drug label for tomoxifin states that the impact of
- 23:06Speaker 3: CYP two D six polymorphisms on the efficacy of tomoxifen
- 23:10Speaker 3: is not well established, but that CYP two D six
- 23:15Speaker 3: poor metabolizers do have lower indoxophin concentrations as compared to intermediate,
- 23:22Speaker 3: normal or ultra rapid metabolizers. So, Angela, can you tell
- 23:27Speaker 3: us how your prescriber decided to order a CYP two
- 23:31Speaker 3: D six PGX test for you?
- 23:35Speaker 5: Sure, it was much h It was again came back
- 23:39Speaker 5: to advocacy on my own part.
- 23:41Speaker 4: It was a very new test.
- 23:44Speaker 5: There had only been very limited data that had been
- 23:47Speaker 5: out on this genetic polymorphism, and the honestly, my oncologists
- 23:58Speaker 5: didn't know what to do the test, and honestly, not
- 24:02Speaker 5: very many other people did either.
- 24:04Speaker 4: Sure, and I'll.
- 24:05Speaker 5: Get to that in just a moment, but I had
- 24:08Speaker 5: meat about it in I believe it was actually uh
- 24:12Speaker 5: JAFFA the Journal for American Pharmacists Association, kind of a little.
- 24:17Speaker 4: You know, blurb. It wasn't a full fledged article. It
- 24:19Speaker 4: was just the.
- 24:21Speaker 5: Pharmacod was very new in two thousand and seven, and
- 24:25Speaker 5: we knew about the interactions through the between tamoxifin and
- 24:32Speaker 5: say anti psychota or excuse me, antidepressant medications like prozac,
- 24:38Speaker 5: and so people had started looking at.
- 24:41Speaker 4: Other other avenues.
- 24:44Speaker 5: And I had already done genetic testing for the for
- 24:50Speaker 5: the causes of cancer or the risk factors for breast cancer,
- 24:54Speaker 5: which was really the only option.
- 24:56Speaker 4: Back then, and it was negative for that.
- 25:00Speaker 5: But so that was why I started looking at genetics
- 25:05Speaker 5: and the I went to the doctor.
- 25:09Speaker 4: I talked to him about this, and I noted, I.
- 25:12Speaker 5: Said, listen, I'm not having any of the typical side
- 25:15Speaker 5: effects you would expect from tomoxifen. I was in menoplause
- 25:20Speaker 5: essentially at that point, but was not having a lot
- 25:23Speaker 5: of the other because of the other chemotherapy agents I
- 25:27Speaker 5: was on and I wasn't but I wasn't having any
- 25:31Speaker 5: of the side effects you would expect with tomoxif and
- 25:34Speaker 5: hot flashes and other things such as that. So he
- 25:39Speaker 5: begrudgingly he said, listen, I will order this test. I
- 25:42Speaker 5: don't know if your insurance is going to cover it.
- 25:44Speaker 5: I kind of got it, and I have no clue
- 25:46Speaker 5: what to do with the.
- 25:47Speaker 4: Results when they come back, So you're going to have
- 25:49Speaker 4: to interpret them yourself.
- 25:51Speaker 5: I said, well, I will do that, and so, of course,
- 25:56Speaker 5: because I had made that deal, it came back.
- 25:59Speaker 4: That I was an innerabilize.
- 26:02Speaker 5: My husband tracked down the person who had done the research.
- 26:08Speaker 5: I believe he was in the Buffalo, New York area,
- 26:11Speaker 5: somewhere in upstate New York.
- 26:13Speaker 4: My husband tracked him down directly because at the time
- 26:17Speaker 4: that there were some.
- 26:19Speaker 5: Baseline guidelines, not necessarily formal guidelines. Yes, but you're a
- 26:24Speaker 5: poor metabolizer, then you stop and you do something different.
- 26:27Speaker 5: If you're a if you're a good or ultra metabolizer,
- 26:32Speaker 5: then you stay the course.
- 26:35Speaker 4: Intermediately had no clue. So again, as a couple, we
- 26:40Speaker 4: kind of researched this.
- 26:41Speaker 5: We did what we could, talk to the doctor, and
- 26:44Speaker 5: we were leaving the area and I was establishing care
- 26:47Speaker 5: in Virginia, where we live now, and so I held
- 26:51Speaker 5: off making a decision until we moved and met with
- 26:55Speaker 5: here in Virginia. I was at a more in a
- 26:57Speaker 5: more academic setting, and she had very different thoughts and
- 27:03Speaker 5: had more background on interpreting those.
- 27:07Speaker 4: Those results.
- 27:08Speaker 5: Okay, so my physician here, my ecologists here, really drove
- 27:14Speaker 5: that decision.
- 27:17Speaker 3: Yeah, you shared with me prior to the podcast if
- 27:19Speaker 3: you were an intermediate metabolizer and you felt like that
- 27:23Speaker 3: was affecting your response to to moxifen, and luckily you
- 27:28Speaker 3: found that physician who did have a better understanding of
- 27:34Speaker 3: pharmacogenomics test results and how to apply them clinically. So
- 27:40Speaker 3: how did your test results impact your physician's decisions about
- 27:45Speaker 3: your treatment? I think that's that is a major take
- 27:49Speaker 3: home message for this episode, is you know what changed?
- 27:55Speaker 5: Sure, she again coupled it with the clinical presentation very
- 28:01Speaker 5: in take to moxifin and say, I never experienced.
- 28:05Speaker 4: Any side effects with it. That's not a common response
- 28:10Speaker 4: that have or men. I mean, I guess you could
- 28:15Speaker 4: in some cases potentially have that.
- 28:17Speaker 3: But the.
- 28:22Speaker 4: Because it was coupled with the clinical presentation, she decided
- 28:26Speaker 4: to offer to add.
- 28:28Speaker 5: Lucron to the injections to my therapy regimen.
- 28:35Speaker 4: She did not stop tomoxifen. However, because she indicated.
- 28:41Speaker 5: The studies were there, the data was there supporting five
- 28:46Speaker 5: years of tomoxifen at that point it was five years
- 28:48Speaker 5: that five years of tomoxifen following chemotherapy was the gold standard,
- 28:54Speaker 5: and so she didn't.
- 28:55Speaker 4: Look to stop it in case there.
- 28:58Speaker 5: Was some other benefit to tomoxifin. They had nothing to
- 29:02Speaker 5: do with this. That don't have anything to do with the.
- 29:05Speaker 4: Active metabolite, as you mentioned, because sometimes we find that
- 29:11Speaker 4: that drugs work in ways that we didn't.
- 29:14Speaker 5: Assume they worked. That's her and so she didn't want
- 29:17Speaker 5: to stop it for that reason. So I continued with
- 29:20Speaker 5: both and started lupron injections monthly for the duration of
- 29:26Speaker 5: that five year period. At about the three and a
- 29:29Speaker 5: half year mark on tomoxyfin, I started having extreme headaches
- 29:38Speaker 5: and we did all the.
- 29:39Speaker 4: Testing looking for brain.
- 29:42Speaker 5: Mets and those kinds of things, and it is a
- 29:45Speaker 5: late side effect of tomoxipin, and so for that reason,
- 29:50Speaker 5: I endured it for about six months, and then at
- 29:53Speaker 5: that point my physician decided that you know, I was basically,
- 30:00Speaker 5: you know, my ovaries were completely shut down at that
- 30:02Speaker 5: point and with the loupron and so.
- 30:06Speaker 4: We decided to stop tomoxifen.
- 30:10Speaker 5: I had also discussed at that point whether lupron versus
- 30:15Speaker 5: having my ovaries removed was a better option, right, But
- 30:22Speaker 5: because I was younger than forty at the time, the recommendation,
- 30:28Speaker 5: even if I had been brack a positive, was to keep.
- 30:32Speaker 4: The ovaries and.
- 30:36Speaker 5: Just do more regular testing for ovarian and breast cancer
- 30:41Speaker 5: because of the positive et estrogen effects from sure from
- 30:46Speaker 5: keeping your ovaries, from on both self heart health, all
- 30:50Speaker 5: of those other areas of health that.
- 30:52Speaker 4: We know absolutely positiveness. So she dissuaded me from having
- 30:59Speaker 4: from going that.
- 31:02Speaker 3: Yeah, I'm so glad that you brought that up, because
- 31:07Speaker 3: one of the maybe the side effects or maybe the
- 31:11Speaker 3: not as positive outcomes of pharmacogenomics testing can be the
- 31:17Speaker 3: black and white thinking with physicians that if the test
- 31:24Speaker 3: result comes back and says this drug falls into maybe
- 31:30Speaker 3: not the best option for the patient, they might automatically
- 31:35Speaker 3: reject that drug. And you know, as advocates for pharmacogenomics,
- 31:41Speaker 3: it's important for us to educate prescribers that you have
- 31:46Speaker 3: to use that test information in consideration of all the
- 31:51Speaker 3: other factors that go into choosing and managing medications. And
- 31:59Speaker 3: you know that test result is not an end all
- 32:01Speaker 3: be all, So I'm so glad you brought that up,
- 32:06Speaker 3: because you know, again that is one of my soapbox
- 32:10Speaker 3: topics for pharmacogenomics, is that this is a tool in
- 32:14Speaker 3: the toolbox, is not a magic recipe that we know
- 32:22Speaker 3: exactly how it's going to turn out.
- 32:26Speaker 5: And I do and I do appreciate my physician taking
- 32:29Speaker 5: that stance that recognizing that we think we know why
- 32:34Speaker 5: tomoxifen has a benefit for a certain number of years,
- 32:38Speaker 5: if we're wrong on that, the on the actual mechanism,
- 32:42Speaker 5: or if there's some secondary mechanism mechanism gotten the same exposure.
- 32:50Speaker 4: Or hasn't been studied, or you haven't even found it
- 32:53Speaker 4: yet that might be.
- 32:55Speaker 5: Beneficial that I just immediately stopping it. It was not necessarily
- 33:01Speaker 5: the right choice, and that explanation made a lot of
- 33:03Speaker 5: sense to me. Obviously, if I'd been having horrible side
- 33:07Speaker 5: effects and when I did have the intractable headaches, that
- 33:11Speaker 5: was the time to make that.
- 33:12Speaker 4: That was the time, all right, But at that time I.
- 33:17Speaker 5: Wasn't It wasn't bothering me at all, and so there
- 33:21Speaker 5: was no reason to take that out of the toolbox
- 33:25Speaker 5: at that point.
- 33:26Speaker 3: Sure, sure, And I mean this was years ago and
- 33:29Speaker 3: you guys were making the best decisions you had with
- 33:31Speaker 3: the information you had at the time. You know, we
- 33:35Speaker 3: didn't have some of the published guidelines that we have now,
- 33:38Speaker 3: such as those from the Clinical Pharmacogenetics Implementation Consortium. You know,
- 33:44Speaker 3: they've now published guidelines for the dosing of demoxifen based
- 33:49Speaker 3: on CYP two D six phenotype, with therapeutic recommendations for
- 33:54Speaker 3: each metabolizer phenotype. I mean, you guys didn't have that then,
- 33:59Speaker 3: and you know now for poor metabolizers, Seapick recommends using
- 34:04Speaker 3: an alternative formone therapy such as an aromatase inhibitor, and
- 34:09Speaker 3: that's for postmenopausal women, or an aromatase inhibitor along with
- 34:15Speaker 3: a very infunction suppression in pre menopausal women.
- 34:20Speaker 4: And did right. I didn't have the aromatase. We didn't
- 34:26Speaker 4: have that piece. We considered it. Yeah, I'll be being
- 34:31Speaker 4: pre menopausal. She left me on the tomoxiphone.
- 34:33Speaker 3: And sudden mm hmm. Yeah. And those recommendations are based
- 34:39Speaker 3: on the approaches being superior to tomoxyfin regardless of the CYP
- 34:46Speaker 3: TWOT six genotype, and the knowledge that CYP two D
- 34:50Speaker 3: six poor metabolizers who switched from tomoxifen to a nastrosol
- 34:55Speaker 3: do not have an increased risk of recurrence now SEAPICK Also,
- 35:01Speaker 3: the recommendation also states that higher dose to moxifen, so
- 35:05Speaker 3: forty milligrams per day, can be considered if there are
- 35:10Speaker 3: contra indications to a rheumitation inhibitor therapy. However, the increase
- 35:15Speaker 3: in doxofin concentration among CYP two D six poor metabolizers
- 35:21Speaker 3: that are treated with the higher to moxfin dose doesn't
- 35:25Speaker 3: typically reach the level as in normal metabolizers. So, you know,
- 35:30Speaker 3: while SEAPIT guidelines are available today to guide clinicians in
- 35:34Speaker 3: managing to moxifen, again, you know, they weren't available to
- 35:39Speaker 3: you guys back then. So did your You didn't, I
- 35:43Speaker 3: don't think you mentioned did your doctor adjust your dose
- 35:47Speaker 3: at all? Did she keep you on the same dose?
- 35:50Speaker 4: She kept me on the same dose at that point.
- 35:53Speaker 4: And this I'm an eighteen.
- 35:55Speaker 5: Year survivor at this point, and I was probably sixteen
- 36:00Speaker 5: years ago by the time all the decisions were made.
- 36:03Speaker 5: I probably went a full at least eight or nine months,
- 36:08Speaker 5: maybe a year on tomoxifen with nothing else on board
- 36:13Speaker 5: and then finished out the rest of that five years
- 36:19Speaker 5: with the lupron and then another year and a half
- 36:23Speaker 5: at least on the tomoxifen the dual therapy. But no,
- 36:28Speaker 5: she didn't change the dose. She was sure making educated guesses.
- 36:33Speaker 3: Absolutely, Absolutely, absolutely, It's called practicing medicine because that's what
- 36:38Speaker 3: we do, We practice and we use at this point, yes, absolutely,
- 36:46Speaker 3: I mean, your outcome speaks for itself, right, so we
- 36:49Speaker 3: definitely would not change that outcome.
- 36:52Speaker 4: So and I will.
- 36:54Speaker 5: Say, because I know there are other studies that have
- 36:58Speaker 5: debunked using pharmacogenomics in this area, but I do think
- 37:04Speaker 5: those need to be looked at in terms of the
- 37:07Speaker 5: the age of the patients, whether or not.
- 37:11Speaker 4: I did end up going on and having a.
- 37:14Speaker 5: Bilateral mastectomy about a year after my chem A year
- 37:21Speaker 5: after the first mastectomy, my mass sexty came at the
- 37:25Speaker 5: end of the chemotherapy.
- 37:28Speaker 4: Process.
- 37:29Speaker 5: We moved out of the area within three weeks after
- 37:33Speaker 5: my surgery, not ideal, so I didn't undergo reconstruction at
- 37:36Speaker 5: that time. I waited until we got where we were
- 37:40Speaker 5: and got established, and at the point that I was
- 37:43Speaker 5: ready to have reconstruction for the right side, I had
- 37:47Speaker 5: endured the every three months testing and the breast mriyes
- 37:53Speaker 5: every three months, and the stress and anxiety that came
- 37:56Speaker 5: along with waiting for those results and even meeting to
- 38:00Speaker 5: those tests each three months. And when I went in
- 38:04Speaker 5: for the reconstruction, I requested, I asked whether or not
- 38:08Speaker 5: we could go ahead and do a bilateral mastectomy and
- 38:11Speaker 5: bilateral reconstruction at the same time.
- 38:14Speaker 4: And so I took a more aggressive approach.
- 38:17Speaker 5: Than even what the guidelines probably recommended then, but it
- 38:23Speaker 5: was a personal choice that I went ahead and.
- 38:26Speaker 4: Made at that point. So in looking at my cohort
- 38:30Speaker 4: in some of those.
- 38:31Speaker 5: Studies, a lot of those studies that are evaluating those
- 38:35Speaker 5: types of things and whether or not a poor metabolizer
- 38:38Speaker 5: or an in excuse me, an intermediate metabolizer, whether there
- 38:41Speaker 5: should be a guideline around that there's not a lot
- 38:45Speaker 5: of young blateral mass tectomy patients. Even though there's tens
- 38:55Speaker 5: of thousands of people in those when you drill down,
- 38:58Speaker 5: there's not a lot of me in that study.
- 39:01Speaker 3: Still, Yeah, and that's important because if the study doesn't
- 39:05Speaker 3: have a patient a large portion of patients that look
- 39:09Speaker 3: like you, well, then you can't necessarily extrapolate those results
- 39:14Speaker 3: to you again.
- 39:16Speaker 5: But if I had not had other alternatives, if radiation
- 39:20Speaker 5: had absolutely been what I needed by all means, I
- 39:24Speaker 5: would have done that and dealt with any risk of
- 39:27Speaker 5: that later. But in my case, I was fortunate enough
- 39:31Speaker 5: to have options exactly.
- 39:35Speaker 3: So let's shift gears a little bit. We've talked about pharmacogenomics.
- 39:41Speaker 3: In terms of pharmacokinetics in contrast to CYP two D
- 39:47Speaker 3: six testing, the FDA label does imply that patients should
- 39:54Speaker 3: undergo estrogen receptor testing if the patient consumes tomoxifen. The
- 40:00Speaker 3: label states that the QUBA study showed patients with a
- 40:04Speaker 3: positive estrogen receptor were more likely to benefit from tomoxifen,
- 40:10Speaker 3: and in the nsabp B, a non study in women
- 40:14Speaker 3: age fifty to fifty nine years old, which I know
- 40:17Speaker 3: was not your age group, only women with both estrogen
- 40:21Speaker 3: and progestine receptor levels clearly benefited, while survival results were
- 40:28Speaker 3: poorer in women with both estrogen and progester and receptor
- 40:33Speaker 3: levels less than ten f moles. So did your physician
- 40:41Speaker 3: order estrogen receptor testing, because technically that stuff falls under
- 40:45Speaker 3: pharmacogenomics as well. Did they do that prior to your tomoxifen.
- 40:50Speaker 4: They did, and they did that prior to anything. Honestly, Yeah,
- 40:56Speaker 4: r PR and her too.
- 40:59Speaker 5: Receptor status really drives the chemo elements, That drives everything absolutely,
- 41:08Speaker 5: So that was all.
- 41:09Speaker 4: Done right off with the lumpectomy. So I was estrogen positive.
- 41:16Speaker 5: I was very weakly progesterone positive. I cannot remember the amount.
- 41:23Speaker 5: Some people consider me progesterine positive.
- 41:26Speaker 4: Some doult.
- 41:30Speaker 3: Okay, Yeah, I wanted to make sure that I mentioned
- 41:34Speaker 3: that because sometimes when we think about pharmacogenomics testing, we
- 41:38Speaker 3: don't think about, uh, the indication for the drug and
- 41:42Speaker 3: how that testing impacts whether the drug is indicated. So
- 41:48Speaker 3: there's also an increased incident of thombo embolic events including
- 41:54Speaker 3: DVT and pulmonary embolism during tomoxifen therapy, especially when tomorrow
- 42:00Speaker 3: oxen is co administered with chemotherapy. So the FDA label
- 42:05Speaker 3: again it states that a clinical trial showed no benefit
- 42:10Speaker 3: of screening for fact or five leading or prothombin F
- 42:14Speaker 3: two mutations when treating with timoxfin. Do you remember if
- 42:17Speaker 3: your physician ordered those tests or you haven't mentioned experience
- 42:22Speaker 3: in any type of thrmbolic events.
- 42:26Speaker 4: I did not.
- 42:27Speaker 5: Have a thrombolic event, and I don't believe that I.
- 42:32Speaker 4: Was tested for factor five libraries.
- 42:35Speaker 3: Yeah yeah, yeah, Well, you know, again, it's not necessarily
- 42:41Speaker 3: shown to have clinical utility, and that really leads us
- 42:45Speaker 3: into the last segment of our discussion, and that's clinical utility.
- 42:53Speaker 3: So the National Comprehensive Cancer Network Breast Cancer Guidelines, and
- 42:59Speaker 3: we discussed this prior to recording due to the limited
- 43:03Speaker 3: and conflicting evidence. Currently, they don't recommend CYP two D
- 43:07Speaker 3: six testing as a tool to determine the optimal adjuvant
- 43:12Speaker 3: indocrine strategy. And this recommendation is also consistent with the
- 43:18Speaker 3: American Society of Clinical Oncology guidelines. And you know, NCCN does, however,
- 43:26Speaker 3: think it's reasonable, for example, when prescribing an SSR right
- 43:32Speaker 3: to avoid potent and intermediate CYP TWOD six inhabiting agents.
- 43:38Speaker 3: So it's not that they completely rule out the clinical
- 43:42Speaker 3: utility of the testing for other medications. And I bring
- 43:47Speaker 3: this up because my focus is really on market access
- 43:51Speaker 3: and reimbursement for pharmacogenomic testing, and it's critical to access
- 44:00Speaker 3: and reimbursement these guidelines that we have from these consortiums
- 44:08Speaker 3: that uh review the research and make recommendations and write guidelines.
- 44:15Speaker 3: So that's why I'm bringing it up now. I know
- 44:17Speaker 3: you've told me that, uh, you know, you get you
- 44:22Speaker 3: paid for your test. I don't even know if you
- 44:24Speaker 3: mentioned if you even tried to get your insurer at
- 44:27Speaker 3: the time to reimburse the test, and that they did.
- 44:33Speaker 5: Okay, Also they did pay for it at the time,
- 44:37Speaker 5: and I don't know if they would now or not.
- 44:40Speaker 4: Insurance is very different. We had real in hindsight, we
- 44:44Speaker 4: had amazing insurance then and we would have.
- 44:50Speaker 5: Been in a financial, you know, very difficult situation if
- 44:55Speaker 5: we had the entrance we have now. Everything was covered
- 45:00Speaker 5: and the insurance granted. How good the insurance was, so
- 45:06Speaker 5: that was covered at the time.
- 45:08Speaker 3: Excellent, excellent. So I want to point out to our audience,
- 45:11Speaker 3: because I know a lot of you guys follow me
- 45:13Speaker 3: for my market access and reimbursement insight. I want to
- 45:18Speaker 3: let you guys know that most payers, with one important exception,
- 45:24Speaker 3: do not reimburse CYP two D six testing for timoxfen
- 45:28Speaker 3: despite it being a CPICK level A drug gen pair,
- 45:32Speaker 3: and that one exception is Palmeto GBA's multi X, who
- 45:37Speaker 3: does reimburse CEPICK level A and B drug gen pairs.
- 45:42Speaker 3: So this means that Medicare will reimburse medically necessary CYP
- 45:48Speaker 3: two D six tests for Medicare beneficiaries who obtained the
- 45:54Speaker 3: test from a laboratory in the Muldix Medicare Administrative contractor tear. Now, again,
- 46:03Speaker 3: Angela was much younger than the majority of Medicare patients
- 46:08Speaker 3: except those that maybe are on disability. So I think
- 46:12Speaker 3: it's critical again to point out that payer policy differences.
- 46:22Speaker 3: You know, you were younger, the research possibly didn't apply
- 46:27Speaker 3: to you. There's so many factors, but you were able
- 46:31Speaker 3: to advocate for yourself. You had good payer coverage at
- 46:34Speaker 3: that time, and you're here today to talk about it.
- 46:39Speaker 3: You know, the bright side of this is that many
- 46:43Speaker 3: payers now are deferring the Moldix for their genetic testing
- 46:47Speaker 3: coverage and reimbursement policies. You know, my hope is Angela,
- 46:52Speaker 3: that you're not the exception and that ladies and males
- 46:58Speaker 3: can have breast can as well. You know that they're
- 47:02Speaker 3: able to access this testing, they have the positive outcomes
- 47:06Speaker 3: that you've had, and you know, we our goal, one
- 47:10Speaker 3: of our goals for today was to try to get
- 47:12Speaker 3: this message out. And you know, make this real world
- 47:16Speaker 3: for people that are listening. So thank you again for
- 47:21Speaker 3: joining me on this episode. Is there anything else you'd
- 47:24Speaker 3: like to add to the conversation or can you let
- 47:27Speaker 3: our listeners know how they can reach you if they
- 47:30Speaker 3: might have additional questions or sure.
- 47:33Speaker 5: They're welcome to reach me at a Casano at form
- 47:39Speaker 5: fusion and p H A R M f U s
- 47:45Speaker 5: io N dot com. You're welcome to reach out to me,
- 47:49Speaker 5: whether it's from a clinical standpoint or if you you
- 47:54Speaker 5: know our experience in breast CADS or our family member
- 47:56Speaker 5: is and wants to speak with someone. I think one
- 47:59Speaker 5: of the eye opening things when I was diagnosed young,
- 48:02Speaker 5: and I think, unfortunately we're going to see and we're
- 48:05Speaker 5: already seeing a very young cohort of patients across particularly
- 48:10Speaker 5: breast and colon cancer.
- 48:14Speaker 4: Is everyone that wanted to talk to me and tell
- 48:18Speaker 4: me about.
- 48:18Speaker 5: Their experience and share their experiences with me didn't wasn't me.
- 48:23Speaker 4: They weren't thirty years old with a one year old
- 48:25Speaker 4: running around.
- 48:27Speaker 5: They were much older than I was. And that doesn't
- 48:29Speaker 5: mean their journey wasn't hard. Many of them had terrific
- 48:33Speaker 5: journeys that were much harder than mine, but it was
- 48:38Speaker 5: very discouraging to see and to see the few articles
- 48:44Speaker 5: that I did read that basically indicated my chances as
- 48:48Speaker 5: a young woman with breast cancer weren't great.
- 48:52Speaker 4: And so.
- 48:55Speaker 5: Even my doctor paired me up with a woman that
- 48:58Speaker 5: he wanted me to meet with that was going.
- 49:01Speaker 4: Through her second or third recurrence.
- 49:03Speaker 5: Of breast cancer and it had already gone to her spine,
- 49:08Speaker 5: which again was not an encouraging thing to someone that
- 49:12Speaker 5: was newly diagnosed. So I'm happy to discuss with patients
- 49:18Speaker 5: or with clinicians and feel free to reach out.
- 49:23Speaker 3: Awesome, that's such a very gracious offer to our audience.
- 49:29Speaker 3: And speaking of our audience, thank you guys for tuning in.
- 49:33Speaker 3: Without our faithful listeners, we wouldn't have such a successful
- 49:36Speaker 3: podcast and for that we're very grateful. We love bringing
- 49:40Speaker 3: you the stories, we love bringing you the education. We
- 49:44Speaker 3: do a lot of PGX in here on the Precision
- 49:47Speaker 3: Health in PGX podcasts, PGX Science, Clinical, Application and Business,
- 49:52Speaker 3: and we hope you learned something today. You can listen
- 49:56Speaker 3: to all our episodes on PGX for our X or
- 50:01Speaker 3: your preferred podcast platform such as Apple Podcasts, Spotify, and Podbean.
- 50:07Speaker 3: While you were on the platform. Please leave us a
- 50:09Speaker 3: five star review so our sponsors will continue to make
- 50:12Speaker 3: this podcast possible. We love to hear from you. What
- 50:16Speaker 3: can we teach you? What industry updates do you want
- 50:19Speaker 3: to learn about? Drop us a message on LinkedIn and
- 50:22Speaker 3: let us know. And until next time, here's to precision
- 50:26Speaker 3: health and removing the trial and error from pharmacogenomics.